DXCM — DexCom Inc. stock price and chart

DXCM

$78.56-0.01%

as of close, Oct 27, 2026

☾ AH $78.56 -0.01%

DexCom Inc.Stock · HealthcareS&P 500 Equal Weight · 0.2% of RSPNasdaq-100 · 0.1% of QQQNasdaq Composite · 0.06% of ONEQS&P 500 · 0.04% of SPYMSCI World · 0.04% of URTHRussell 1000 · 0.04% of IWBUS Stock Market · 0.04% of VTIRussell 3000 · 0.04% of IWVMSCI ACWI · 0.03% of ACWI

PeersGEHCSTEZBHPHGEWPODD

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEESEEEEEEEEEEEEEEEEE

20162019202120242026

20.040.060.080.0100.0120.0140.0160.00100.0M$78.56

2026-10-27

Price$78.56

MA20$79.67

MA50$72.30

Vol27.2M

What would $1,000 invested in DXCM be worth today? →

DXCM returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $78.56
YTD price return: +18.37%
YTD total return: +18.37%
Next earnings: Oct 29, 2026 · After close
Market cap: 29.6B2016-12 5B2026-10 29.6B+487.5% over the window
Enterprise value: 28.7B
Shares outstanding: 377.4M2016-06 335.5M2026-06 377.4M+12.5% over the window
52W low: $54.11
52W high: $92.59
From 52W high: -15.15%
From 52W low: +45.19%
52W range: 64%
Beta: 1.42

Volume

Rel volume: 1.19×
30D volume: 4.3M
30D $ vol: 367.3M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1M0 insider-days of buying (no priced lot) and 1 of selling ($145K) in the last 30 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$145K
Insider net 3M0 insider-days of buying (no priced lot) and 12 of selling ($4.7M) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$4.7M
Insider net 1Y0 insider-days of buying (no priced lot) and 25 of selling ($12.3M) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$12.3M

Form 4 transactions by trade date, as filed; latest on file 2026-10-15.

Fundamentals

Sales (ttm): 5B2016-06 489.5M2026-06 5B+915.2% over the window
Sales/share: $13.172016-06 $1.462026-06 $13.17+802.6% over the window
EPS (ttm): $2.512016-06 -$0.242026-06 $2.51-1146.0% over the window
FCF (ttm): 1.4B2016-06 8.1M2026-06 1.4B+17245.7% over the window
FCF/share: $3.722016-06 $0.022026-06 $3.72+15323.1% over the window
Book value/share: $6.952016-06 $0.732026-06 $6.95+846.0% over the window
Net margin: 20.12%2016-06 -16.4%2026-06 20.1%-222.5% over the window
ROE: 38.14%2016-06 -32.6%2026-06 38.1%-216.9% over the window
ROA: 15.49%2016-06 -24.2%2026-06 15.5%-164.1% over the window
Current ratio: 1.732016-06 3.262026-06 1.73-46.9% over the window

Growth (CAGR, ttm) · 10Y

Sales: +15.55%2025-06-30 → 2026-06-304.3B → 5B (+15.5% total)+15.83%2023-06-30 → 2026-06-303.2B → 5B (+55.4% total)+18.03%2021-06-30 → 2026-06-302.2B → 5B (+129.0% total)+26.09%2016-06-30 → 2026-06-30489.5M → 5B (+915.2% total)
Net income: +74.99%2025-06-30 → 2026-06-30571.5M → 999.7M (+74.9% total)+40.87%2023-06-30 → 2026-06-30357.5M → 999.7M (+179.6% total)+10.08%2021-06-30 → 2026-06-30618.4M → 999.7M (+61.7% total)n/a
FCF: +146.30%2025-06-30 → 2026-06-30570.8M → 1.4B (+146.1% total)+44.45%2023-06-30 → 2026-06-30466M → 1.4B (+201.5% total)+69.49%2021-06-30 → 2026-06-30100.5M → 1.4B (+1298.0% total)+67.47%2016-06-30 → 2026-06-308.1M → 1.4B (+17245.7% total)
Shares: -3.78%2025-06-30 → 2026-06-30392.2M → 377.4M (-3.8% total)-0.91%2023-06-30 → 2026-06-30387.9M → 377.4M (-2.7% total)-0.50%2021-06-30 → 2026-06-30387M → 377.4M (-2.5% total)+1.18%2016-06-30 → 2026-06-30335.5M → 377.4M (+12.5% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +79.68%2025-06-30 → 2026-06-30$1.40 → $2.51 (+79.6% total)+44.10%2023-06-30 → 2026-06-30$0.84 → $2.51 (+199.3% total)+12.37%2021-06-30 → 2026-06-30$1.40 → $2.51 (+79.2% total)n/a
Sales/share: +20.09%2025-06-30 → 2026-06-30$10.97 → $13.17 (+20.1% total)+16.89%2023-06-30 → 2026-06-30$8.24 → $13.17 (+59.7% total)+18.62%2021-06-30 → 2026-06-30$5.61 → $13.17 (+134.9% total)+24.61%2016-06-30 → 2026-06-30$1.46 → $13.17 (+802.6% total)
FCF/share: +155.96%2025-06-30 → 2026-06-30$1.46 → $3.72 (+155.8% total)+45.78%2023-06-30 → 2026-06-30$1.20 → $3.72 (+209.9% total)+70.34%2021-06-30 → 2026-06-30$0.26 → $3.72 (+1333.7% total)+65.52%2016-06-30 → 2026-06-30$0.02 → $3.72 (+15323.1% total)
Book value/share: +5.88%2025-06-30 → 2026-06-30$6.56 → $6.95 (+5.9% total)+8.65%2023-06-30 → 2026-06-30$5.42 → $6.95 (+28.3% total)+6.12%2021-06-30 → 2026-06-30$5.16 → $6.95 (+34.6% total)+25.20%2016-06-30 → 2026-06-30$0.73 → $6.95 (+846.0% total)
Price: +11.24%2025-10-27 → 2026-10-27$70.63 → $78.56 (+11.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-4.18%2023-10-27 → 2026-10-27$89.29 → $78.56 (-12.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-10.87%2021-10-27 → 2026-10-27$139.64 → $78.56 (-43.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+15.06%2016-10-26 → 2026-10-27$19.31 → $78.56 (+306.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +11.24%2025-10-27 → 2026-10-27$70.63 → $78.56 (+11.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-4.18%2023-10-27 → 2026-10-27$89.29 → $78.56 (-12.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-10.87%2021-10-27 → 2026-10-27$139.64 → $78.56 (-43.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+15.06%2016-10-26 → 2026-10-27$19.31 → $78.56 (+306.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 31.2×2016-12 -89.002026-10 29.65-133.3% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 26.0×2016-12 -89.792026-10 26.03-129.0% over the window
Fwd P/E: 25.0×
P/S (ttm)Market cap ÷ TTM revenue.: 6.0×2016-12 9.472026-10 5.97-37.0% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 11.3×2016-12 19.272026-10 11.31-41.3% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 21.1×2016-12 1121.352026-10 21.10-98.1% over the window
EV/EBITDA (fy): 20.5×
EV/Sales (ttm): 5.8×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 4.74%2016-09 0.1%2026-06 5.4%+5995.9% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 377.4M ÷ 392.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 3.78%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (3.78%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($34.2B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 3.78%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($1.1B) ÷ today's market cap ($29.6B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 3.63%2016-09 -0.3%2026-06 4.2%-1755.7% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $1.1B + TTM dividends $0) ÷ today's market cap ($29.6B). Same caveat as the cash buyback yield.: 3.63%2016-09 -0.3%2026-06 4.2%-1755.7% over the window

Vs own 10Y history

P/E: 4th
P/OI: 4th
P/S: 8th
P/B: 11th
P/FCF: 4th

Bar = where today’s multiple sits in DXCM’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-27#

-0.01%

-8.37%

-9.31%

+7.07%

YTD

+18.37%

+11.23%

-43.74%

Recent filings#

Sep 148-K · Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Sep 108-K · Dexcom Appoints Glenn Boehnlein to Board of Directors
Jul 30Earnings · Earnings release — EPS $0.70 vs $0.61 est. (+14.8%); revenue $1.31B (+13% y/y) 12.0%

All filings and insider trades →

Financial statements

Open full DXCM financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+8.32%	+0.22%
JNJ	Johnson & Johnson	-0.92%	+0.91%
ABBV	AbbVie Inc.	+8.34%	-0.12%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+8.98%	-0.08%
MRK	Merck & Co. Inc.	-4.68%	+0.86%
NVS	Novartis AG	+7.84%	+1.98%
TMO	Thermo Fisher Scientific Inc.	+2.67%	+1.19%
AMGN	Amgen Inc.	+8.04%	+0.75%

DXCM — DexCom Inc. price, chart and key statistics